177 related articles for article (PubMed ID: 28151704)
1. Urinary Melatonin in Relation to Postmenopausal Breast Cancer Risk According to Melatonin 1 Receptor Status.
Devore EE; Warner ET; Eliassen AH; Brown SB; Beck AH; Hankinson SE; Schernhammer ES
Cancer Epidemiol Biomarkers Prev; 2017 Mar; 26(3):413-419. PubMed ID: 28151704
[No Abstract] [Full Text] [Related]
2. Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women.
Schernhammer ES; Berrino F; Krogh V; Secreto G; Micheli A; Venturelli E; Sieri S; Sempos CT; Cavalleri A; Schünemann HJ; Strano S; Muti P
J Natl Cancer Inst; 2008 Jun; 100(12):898-905. PubMed ID: 18544743
[TBL] [Abstract][Full Text] [Related]
3. Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort.
Schernhammer ES; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):74-9. PubMed ID: 19124483
[TBL] [Abstract][Full Text] [Related]
4. Urinary melatonin concentration and the risk of breast cancer in Nurses' Health Study II.
Brown SB; Hankinson SE; Eliassen AH; Reeves KW; Qian J; Arcaro KF; Wegrzyn LR; Willett WC; Schernhammer ES
Am J Epidemiol; 2015 Feb; 181(3):155-62. PubMed ID: 25587174
[TBL] [Abstract][Full Text] [Related]
5. Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort.
Schernhammer ES; Berrino F; Krogh V; Secreto G; Micheli A; Venturelli E; Grioni S; Sempos CT; Cavalleri A; Schünemann HJ; Strano S; Muti P
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):729-37. PubMed ID: 20200429
[TBL] [Abstract][Full Text] [Related]
6. Urinary melatonin levels and breast cancer risk.
Schernhammer ES; Hankinson SE
J Natl Cancer Inst; 2005 Jul; 97(14):1084-7. PubMed ID: 16030307
[TBL] [Abstract][Full Text] [Related]
7. Melatonin and breast cancer: a prospective study.
Travis RC; Allen DS; Fentiman IS; Key TJ
J Natl Cancer Inst; 2004 Mar; 96(6):475-82. PubMed ID: 15026473
[TBL] [Abstract][Full Text] [Related]
8. Urinary levels of melatonin and risk of postmenopausal breast cancer: women's health initiative observational cohort.
Sturgeon SR; Doherty A; Reeves KW; Bigelow C; Stanczyk FZ; Ockene JK; Liu S; Manson JE; Neuhouser ML
Cancer Epidemiol Biomarkers Prev; 2014 Apr; 23(4):629-37. PubMed ID: 24510738
[TBL] [Abstract][Full Text] [Related]
9. Urinary Melatonin in Relation to Breast Cancer Risk: Nested Case-Control Analysis in the DOM Study and Meta-analysis of Prospective Studies.
Wong ATY; Fensom GK; Key TJ; Onland-Moret NC; Tong TYN; Travis RC
Cancer Epidemiol Biomarkers Prev; 2021 Jan; 30(1):97-103. PubMed ID: 33144281
[TBL] [Abstract][Full Text] [Related]
10. Association of urinary levels of 6-sulfatoxymelatonin (aMT6s) with prevalent and incident hypertension.
Pérez-Caraballo AM; Ma Y; Ockene JK; Reeves KW; Balasubramanian R; Stanczyk FZ; Allison MA; Chen C; Wang L; Manson JE; Sturgeon SR
Chronobiol Int; 2018 Aug; 35(8):1115-1121. PubMed ID: 29750588
[TBL] [Abstract][Full Text] [Related]
11. Sleep duration, spot urinary 6-sulfatoxymelatonin levels and risk of breast cancer among Chinese women in Singapore.
Wu AH; Stanczyk FZ; Wang R; Koh WP; Yuan JM; Yu MC
Int J Cancer; 2013 Feb; 132(4):891-6. PubMed ID: 22644618
[TBL] [Abstract][Full Text] [Related]
12. First-morning urinary melatonin and breast cancer risk in the Guernsey Study.
Wang XS; Tipper S; Appleby PN; Allen NE; Key TJ; Travis RC
Am J Epidemiol; 2014 Mar; 179(5):584-93. PubMed ID: 24418683
[TBL] [Abstract][Full Text] [Related]
13. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
Tworoger SS; Missmer SA; Barbieri RL; Willett WC; Colditz GA; Hankinson SE
J Natl Cancer Inst; 2005 Apr; 97(8):595-602. PubMed ID: 15840882
[TBL] [Abstract][Full Text] [Related]
14. Urinary melatonin and risk of ovarian cancer.
Poole EM; Schernhammer E; Mills L; Hankinson SE; Tworoger SS
Cancer Causes Control; 2015 Oct; 26(10):1501-6. PubMed ID: 26223889
[TBL] [Abstract][Full Text] [Related]
15. Urinary estrogen metabolites and breast cancer: a combined analysis of individual level data.
Dallal CM; Stone RA; Cauley JA; Ness RB; Vogel VG; Fentiman IS; Fowke JH; Krogh V; Loft S; Meilahn EN; Muti P; Olsen A; Overvad K; Sieri S; Tjønneland A; Ursin G; Wellejus A; Taioli E
Int J Biol Markers; 2013 Apr; 28(1):3-16. PubMed ID: 22865302
[TBL] [Abstract][Full Text] [Related]
16. Urine melatonin levels are inversely associated with sarcopenia in postmenopausal women.
Lee JY; Kim JH; Lee DC
Menopause; 2014 Jan; 21(1):39-44. PubMed ID: 23760432
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
Krajcik RA; Borofsky ND; Massardo S; Orentreich N
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1566-73. PubMed ID: 12496045
[TBL] [Abstract][Full Text] [Related]
18. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
Missmer SA; Eliassen AH; Barbieri RL; Hankinson SE
J Natl Cancer Inst; 2004 Dec; 96(24):1856-65. PubMed ID: 15601642
[TBL] [Abstract][Full Text] [Related]
19. Urinary 6-sulfatoxymelatonin and mammographic density in Japanese women.
Nagata C; Matsubara T; Hara T; Fujita H; Nagao Y; Yamamoto S; Shibuya C; Kashiki Y; Shimizu H
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2509-12. PubMed ID: 18006946
[TBL] [Abstract][Full Text] [Related]
20. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women.
Tamimi RM; Byrne C; Colditz GA; Hankinson SE
J Natl Cancer Inst; 2007 Aug; 99(15):1178-87. PubMed ID: 17652278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
